The complexity of prostate cancer: Genomic alterations and heterogeneity

Nature Reviews Urology

Volumn 9, Issue 11, 2012, Pages 652-664

  Boyd, Lara K ^a   Mao, Xueying ^a   Lu, Yong Jie ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GROWTH; CANCER RISK; CARCINOGENESIS; CHROMOSOME DELETION; CHROMOSOME DUPLICATION; CHROMOSOME INSERTION; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION; COPY NUMBER VARIATION; GENE FUSION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; HUMAN; MALE; MICROSATELLITE INSTABILITY; MUTATIONAL ANALYSIS; POINT MUTATION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; SYSTEMATIC REVIEW; GENETIC HETEROGENEITY; GENETICS; MUTATION; PROSTATE TUMOR;

TUMOR MARKER;

BIOMARKERS, TUMOR; CARCINOGENESIS; GENETIC HETEROGENEITY; HUMANS; MALE; MUTATION; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS;

EID: 84869024543     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2012.185     Document Type: Review

References (230)

1. Ruijter, E. T., van de Kaa, C. A., Schalken, J. A., Debruyne, F. M. & Ruiter, D. J. Histological grade heterogeneity in multifocal prostate cancer: Biological and clinical implications. J. Pathol. 180, 295-299 (1996). (Pubitemid 26393679)
2. Qian, J., Jenkins, R. B. & Bostwick, D. G. Chromosomal anomalies in atypical adenomatous hyperplasia and carcinoma of the prostate using fluorescence in situ hybridization. Urology 46, 837-842 (1995).
3. Miller, G. J. & Cygan, J. M. Morphology of prostate cancer: the effects of multifocality on histological grade, tumor volume and capsule penetration. J. Urol. 152, 1709-1713 (1994). (Pubitemid 24322612)
4. Greene, D. R., Wheeler, T. M., Egawa, S., Dunn, J. K. & Scardino, P. T. A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate. J. Urol. 146, 1069-1076 (1991).
5. Villers, A., McNeal, J. E., Freiha, F. S. & Stamey, T. A. Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors. Cancer 70, 2313-2318 (1992).
6. Arora, R. et al. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer 100, 2362-2366 (2004). (Pubitemid 38657883)
7. Stamatiou, K. N. et al. The phenomenon of multifocality does not affect the biologic behavior of histologic prostate carcinoma. Med. Sci. Monit. 15, BR61-BR63 (2009).
8. Humphrey, P. A. Gleason grading and prognostic factors in carcinoma of the prostate. Mod. Pathol. 17, 292-306 (2004). (Pubitemid 41646608)
9. Carter, B. S., Beaty, T. H., Steinberg, G. D., Childs, B. & Walsh, P. C. Mendelian inheritance of familial prostate cancer. Proc. Natl Acad. Sci. USA 89, 3367-3371 (1992).
10. Edwards, S. M. & Eeles, R. A. Unravelling the genetics of prostate cancer. Am. J. Med. Genet. C Semin. Med. Genet. 129C, 65-73 (2004). (Pubitemid 38989133)
11. Gudmundsson, J. et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat. Genet. 39, 631-637 (2007). (Pubitemid 46676102)
12. Yeager, M. et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat. Genet. 39, 645-649 (2007). (Pubitemid 46676108)
13. Gudmundsson, J. et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat. Genet. 39, 977-983 (2007). (Pubitemid 47185170)
14. Gudmundsson, J. et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat. Genet. 40, 281-283 (2008). (Pubitemid 351311771)
15. Eeles, R. A. et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat. Genet. 40, 316-321 (2008). (Pubitemid 351311772)
16. Thomas, G. et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat. Genet. 40, 310-315 (2008). (Pubitemid 351311773)
17. Gudmundsson, J. et al. Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat. Genet. 41, 1122-1126 (2009).
18. Eeles, R. A. et al. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat. Genet. 41, 1116-1121 (2009).
19. Yeager, M. et al. Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat. Genet. 41, 1055-1057 (2009).
20. Al Olama, A. A. et al. Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat. Genet. 41, 1058-1060 (2009).
21. Easton, D. F. et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447, 1087-1093 (2007). (Pubitemid 47014426)
22. Amundadottir, L. T. et al. A common variant associated with prostate cancer in European and African populations. Nat. Genet. 38, 652-658 (2006). (Pubitemid 43927306)
23. Haiman, C. A. et al. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat. Genet. 39, 638-644 (2007). (Pubitemid 46676106)
24. Takata, R. et al. Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nat. Genet. 42, 751-754 (2010).
25. Mao, X., Young, B. D. & Lu, Y. J. The application of single nucleotide polymorphism microarrays in cancer research. Curr. Genom. 8, 219-228 (2007). (Pubitemid 47232962)
26. Emanuel, B. S. & Saitta, S. C. From microscopes to microarrays: dissecting recurrent chromosomal rearrangements. Nat. Rev. Genet. 8, 869-883 (2007). (Pubitemid 47609084)
27. Boyd, L. K., Mao, X. & Lu, Y.-J. Use of SNPs in cancer predisposition analysis, diagnosis and prognosis: tools and prospects. Expert Opin.Med. Diagnost. 3, 313-326 (2009).
28. Smith, J. R. et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 274, 1371-1374 (1996). (Pubitemid 26391460)
29. Carpten, J. et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat. Genet. 30, 181-184 (2002).
30. Xu, J. Combined analysis of hereditary prostate cancer linkage to 1q24-25: results from 772 hereditary prostate cancer families from the International Consortium for Prostate Cancer Genetics. Am. J. Hum. Genet. 66, 945-957 (2000). (Pubitemid 30470496)
31. Berthon, P. et al. Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am. J. Hum. Genet. 62, 1416-1424 (1998). (Pubitemid 28307111)
32. Gibbs, M. et al. Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am. J. Hum. Genet. 64, 776-787 (1999). (Pubitemid 30460420)
33. Tavtigian, S. V. et al. A candidate prostate cancer susceptibility gene at chromosome 17p. Nat. Genet. 27, 172-180 (2001). (Pubitemid 32157444)
34. Berry, R. et al. Evidence for a prostate cancer-susceptibility locus on chromosome 20. Am. J. Hum. Genet. 67, 82-91 (2000). (Pubitemid 30481546)
35. Xu, J. et al. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat. Genet. 20, 175-179 (1998). (Pubitemid 28455451)
36. Schaid, D. J. et al. Comparison of microsatellites versus single-nucleotide polymorphisms in a genome linkage screen for prostate cancer-susceptibility loci. Am. J. Hum. Genet. 75, 948-965 (2004). (Pubitemid 39532066)
37. Easton, D. F., Schaid, D. J., Whittemore, A. S. & Isaacs, W. J. Where are the prostate cancer genes?-A summary of eight genome wide searches. Prostate 57, 261-269 (2003). (Pubitemid 37487071)
38. Schaid, D. J. The complex genetic epidemiology of prostate cancer. Hum. Mol. Genet. 13, R103-R121 (2004). (Pubitemid 38443804)
39. Xu, J. et al. Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer. Am. J. Hum. Genet. 68, 901-911 (2001). (Pubitemid 32289736)
40. Xu, J. et al. Genome-wide scan for prostate cancer susceptibility genes in the Johns Hopkins hereditary prostate cancer families. Prostate 57, 320-325 (2003). (Pubitemid 37487077)
41. Wiklund, F. et al. Genome-wide scan of Swedish families with hereditary prostate cancer: suggestive evidence of linkage at 5q11.2 and 19p13.3. Prostate 57, 290-297 (2003). (Pubitemid 37487074)
42. Schleutker, J. et al. Genome-wide scan for linkage in finnish hereditary prostate cancer (HPC) families identifies novel susceptibility loci at 11q14 and 3p25-26. Prostate 57, 280-289 (2003). (Pubitemid 37487073)
43. Lange, E. M. et al. Genome-wide scan for prostate cancer susceptibility genes using families from the University of Michigan prostate cancer genetics project finds evidence for linkage on chromosome 17 near BRCA1. Prostate 57, 326-334 (2003).
44. Gillanders, E. M. et al. Combined genome-wide scan for prostate cancer susceptibility genes. J. Natl Cancer Inst. 96, 1240-1247 (2004). (Pubitemid 39232715)
45. Ewing, C. M. et al. Germline mutations in HOXB13 and prostate-cancer risk. N. Engl. J. Med. 366, 141-149 (2012).
46. Suarez, B. K. et al. Replication linkage study for prostate cancer susceptibility genes. Prostate 45, 106-114 (2000).
47. Edwards, S. et al. Results of a genome-wide linkage analysis in prostate cancer families ascertained through the ACTANE consortium. Prostate 57, 270-279 (2003).
48. Janer, M. et al. Genomic scan of 254 hereditary prostate cancer families. Prostate 57, 309-319 (2003). (Pubitemid 37487076)
49. Xu, J. et al. Linkage and association studies of prostate cancer susceptibility: evidence for linkage at 8p22-23. Am. J. Hum. Genet. 69, 341-350 (2001). (Pubitemid 32695206)
50. Hsieh, C. L. et al. A genome screen of families with multiple cases of prostate cancer: evidence of genetic heterogeneity. Am. J. Hum. Genet. 69, 148-158 (2001).
51. Freedman, M. L. et al. AdmiXture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc. Natl Acad. Sci. USA 103, 14068-14073 (2006). (Pubitemid 44452981)
52. Ahn, J. et al. Prostate cancer predisposition loci and risk of metastatic disease and prostate cancer recurrence. Clin. Cancer Res. 17, 1075-1081 (2011).
53. Pomerantz, M. M. et al. Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet. 6, e1001204 (2010).
54. Chang, B. L. et al. Validation of genome-wide prostate cancer associations in men of African descent. Cancer Epidemiol. Biomarkers Prev. 20, 23-32 (2011).
55. Sun, J. et al. Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat. Genet. 40, 1153-1155 (2008).
56. Wasserman, N. F., Aneas, I. & Nobrega, M. A. An 8q24 gene desert variant associated with prostate cancer risk confers differential in vivo activity to a MYC enhancer. Genome Res. 20, 1191-1197 (2010).
57. Sotelo, J. et al. Long-range enhancers on 8q24 regulate c-Myc. Proc. Natl Acad. Sci. USA 107, 3001-3005 (2010).
58. Kote-Jarai, Z. et al. Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript. Hum. Genet. 129, 687-694 (2011).
59. Kote-Jarai, Z. et al. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat. Genet. 43, 785-791 (2011).
60. Wang, D. et al. Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature 474, 390-394 (2011).
61. Mao, X. et al. Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. Cancer Res. 70, 5207-5212 (2010).
62. Mhatre, A. N. et al. Reduced transcriptional regulatory competence of the androgen receptor in X-linked spinal and bulbar muscular atrophy. Nat. Genet. 5, 184-188 (1993). (Pubitemid 23293456)
63. Beilin, J., Ball, E. M., Favaloro, J. M. & Zajac, J. D. Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines. J. Mol. Endocrinol. 25, 85-96 (2000). (Pubitemid 30617076)
64. Simanainen, U. et al. Length of the human androgen receptor glutamine tract determines androgen sensitivity in vivo. Mol. Cell Endocrinol. 342, 81-86 (2011).
65. Kumar, R. et al. Role of the androgen receptor CAG repeat polymorphism in prostate cancer, and spinal and bulbar muscular atrophy. Life Sci. 88, 565-571 (2011).
66. Hsing, A. W. et al. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Res. 60, 5111-5116 (2000).
67. Buchanan, G., Irvine, R. A., Coetzee, G. A. & Tilley, W. D. Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer Metastasis Rev. 20, 207-223 (2001). (Pubitemid 34595269)
68. Gu, M., Dong, X., Zhang, X. & Niu, W. The CAG repeat polymorphism of androgen receptor gene and prostate cancer: a meta-analysis. Mol. Biol. Rep. 39, 2615-2624 (2012).
69. Hsing, A. W. et al. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemiol. Biomarkers Prev. 10, 1077-1082 (2001). (Pubitemid 32959155)
70. Makridakis, N. M. et al. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 354, 975-978 (1999). (Pubitemid 29438402)
71. Lindstrom, S. et al. Systematic replication study of reported genetic associations in prostate cancer: Strong support for genetic variation in the androgen pathway. Prostate 66, 1729-1743 (2006). (Pubitemid 44893899)
72. Ntais, C., Polycarpou, A. & Ioannidis, J. P. Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol. Biomarkers Prev. 12, 120-126 (2003). (Pubitemid 36194001)
73. Mononen, N. & Schleutker, J. Polymorphisms in genes involved in androgen pathways as risk factors for prostate cancer. J. Urol. 181, 1541-1549 (2009).
74. Ross, R. K. et al. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res. 58, 4497-4504 (1998). (Pubitemid 28480602)
75. Ntais, C., Polycarpou, A. & Ioannidis, J. P. SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis. Cancer Epidemiol. Biomarkers Prev. 12, 618-624 (2003). (Pubitemid 36899841)
76. Dong, J. T. Prevalent mutations in prostate cancer. J. Cell Biochem. 97, 433-447 (2006).
77. Grignon, D. J. et al. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J. Natl Cancer Inst. 89, 158-165 (1997). (Pubitemid 27034792)
78. Quinn, D. I. et al. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy. Cancer Res. 60, 1585-1594 (2000). (Pubitemid 30183429)
79. Carter, B. S., Epstein, J. I. & Isaacs, W. B. ras gene mutations in human prostate cancer. Cancer Res. 50, 6830-6832 (1990). (Pubitemid 20361076)
80. Capella, G., Cronauer-Mitra, S., Pienado, M. A. & Perucho, M. Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors. Environ. Health Perspect. 93, 125-131 (1991).
81. Gumerlock, P. H., Poonamallee, U. R., Meyers, F. J. & deVere White, R. W. Activated ras alleles in human carcinoma of the prostate are rare. Cancer Res. 51, 1632-1637 (1991).
82. Konishi, N. et al. K-ras activation and ras p21 expression in latent prostatic carcinoma in Japanese men. Cancer 69, 2293-2299 (1992).
83. Cho, N. Y. et al. BRAF and KRAS mutations in prostatic adenocarcinoma. Int. J. Cancer 119, 1858-1862 (2006).
84. Zheng, L. et al. Unique substitution of CHEK2 and TP53 mutations implicated in primary prostate tumors and cancer cell lines. Hum. Mutat. 27, 1062-1063 (2006).
85. Wu, X., Dong, X., Liu, W. & Chen, J. Characterization of CHEK2 mutations in prostate cancer. Hum. Mutat. 27, 742-747 (2006). (Pubitemid 44205067)
86. Huusko, P. et al. Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nat. Genet. 36, 979-983 (2004). (Pubitemid 39167494)
87. Casey, G. et al. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat. Genet. 32, 581-583 (2002). (Pubitemid 35435169)
88. Urisman, A. et al. Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog. 2, e25 (2006).
89. Douglas, D. A. et al. Novel mutations of epidermal growth factor receptor in localized prostate cancer. Front. Biosci. 11, 2518-2525 (2006). (Pubitemid 43810020)
90. Wong, O. G. et al. Plexin-B1 mutations in prostate cancer. Proc. Natl Acad. Sci. USA 104, 19040-19045 (2007).
91. Sun, X. et al. Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. Nat. Genet. 37, 407-412 (2005).
92. Chen, C. et al. Deletion, mutation, and loss of expression of KLF6 in human prostate cancer. Am. J. Pathol. 162, 1349-1354 (2003). (Pubitemid 36350678)
93. Berger, M. F. et al. The genomic complexity of primary human prostate cancer. Nature 470, 214-220 (2011).
94. Kan, Z. et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466, 869-873 (2010).
95. Barbieri, C. E. et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 44, 685-689 (2012).
96. Grasso, C. S. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239-243 (2012).
97. Kumar, A. et al. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc. Natl Acad. Sci. USA 108, 17087-17092 (2011).
98. Taplin, M. E. et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 332, 1393-1398 (1995).
99. Marcelli, M. et al. Androgen receptor mutations in prostate cancer. Cancer Res. 60, 944-949 (2000). (Pubitemid 30129530)
100. Feldman, B. J. & Feldman, D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 1, 34-45 (2001). (Pubitemid 33741879)
101. Koivisto, P. et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 57, 314-319 (1997). (Pubitemid 27036612)
102. Gregory, C. W. et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 61, 4315-4319 (2001). (Pubitemid 32685750)
103. Linja, M. J. et al. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 61, 3550-3555 (2001). (Pubitemid 32694958)
104. Gottlieb, B., Beitel, L. K., Wu, J. H. & Trifiro, M. The androgen receptor gene mutations database (ARDB): 2004 update. Hum. Mutat. 23, 527-533 (2004). (Pubitemid 38720602)
105. Veldscholte, J. et al. Unusual specificity of the androgen receptor in the human prostate tumor cell line LNCaP: high affinity for progestagenic and estrogenic steroids. Biochim. Biophys. Acta 1052, 187-194 (1990). (Pubitemid 20113181)
106. Taplin, M. E. et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res. 59, 2511-2515 (1999).
107. Nupponen, N. N. & Visakorpi, T. Molecular cytogenetics of prostate cancer. Microsc. Res. Tech. 51, 456-463 (2000).
108. Dong, J. T. Chromosomal deletions and tumor suppressor genes in prostate cancer. Cancer Metastasis Rev. 20, 173-193 (2001).
109. Narla, G. et al. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science 294, 2563-2566 (2001). (Pubitemid 34027299)
110. Clark, J. et al. Genome-wide screening for complete genetic loss in prostate cancer by comparative hybridization onto cDNA microarrays. Oncogene 22, 1247-1252 (2003). (Pubitemid 36363389)
111. Paris, P. L. et al. Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum. Mol. Genet. 13, 1303-1313 (2004). (Pubitemid 38961638)
112. Liu, W. et al. Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer. Neoplasia 10, 897-907 (2008).
113. Taylor, B. S. et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22 (2010).
114. Futreal, P. A. et al. A census of human cancer genes. Nat. Rev. Cancer 4, 177-183 (2004). (Pubitemid 38337497)
115. Greaves, M. F. & Wiemels, J. Origins of chromosome translocations in childhood leukaemia. Nat. Rev. Cancer 3, 639-649 (2003). (Pubitemid 37328819)
116. Mitelman, F., Johansson, B. & Mertens, F. The impact of translocations and gene fusions on cancer causation. Nat. Rev. Cancer 7, 233-245 (2007). (Pubitemid 46480968)
117. Veronese, M. L., Bullrich, F., Negrini, M. & Croce, C. M. The t(6;16)(p21;q22) chromosome translocation in the LNCaP prostate carcinoma cell line results in a tpc/hpr fusion gene. Cancer Res. 56, 728-732 (1996). (Pubitemid 26055459)
118. Edwards, P. A. Fusion genes and chromosome translocations in the common epithelial cancers. J. Pathol. 220, 244-254 (2010).
119. Tomlins, S. A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644-648 (2005). (Pubitemid 41528150)
120. Soda, M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561-566 (2007). (Pubitemid 47206930)
121. Nowell, P. C. & Hungerford, D. A. Chromosome studies on normal and leukemic human leukocytes. J. Natl Cancer Inst. 25, 85-109 (1960).
122. Mehra, R. et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod. Pathol. 20, 538-544 (2007). (Pubitemid 46631996)
123. Lapointe, J. et al. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod. Pathol. 20, 467-473 (2007). (Pubitemid 46482370)
124. Winnes, M., Lissbrant, E., Damber, J. E. & Stenman, G. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. Oncol. Rep. 17, 1033-1036 (2007).
125. Perner, S. et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am. J. Surg. Pathol. 31, 882-888 (2007). (Pubitemid 47165141)
126. Nam, R. K. et al. Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol. Ther. 6, 40-45 (2007). (Pubitemid 46294173)
127. Demichelis, F. et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26, 4596-4599 (2007). (Pubitemid 47037039)
128. Bott, S. R., Arya, M., Shergill, I. S. & Williamson, M. Molecular changes in prostatic cancer. Surg. Oncol. 14, 91-104 (2005). (Pubitemid 41213303)
129. Liu, W. et al. Multiple genomic alterations on 21q22 predict various TMPRSS2/ERG fusion transcripts in human prostate cancers. Genes Chromosomes Cancer 46, 972-980 (2007). (Pubitemid 47502837)
130. Carver, B. S. et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat. Genet. 41, 619-624 (2009).
131. Mani, R. S. et al. Induced chromosomal proXimity and gene fusions in prostate cancer. Science 326, 1230 (2009).
132. Lin, C. et al. Nuclear receptor-induced chromosomal proXimity and DNA breaks underlie specific translocations in cancer. Cell 139, 1069-1083 (2009).
133. Bastus, N. et al. Androgen-induced TMPRSS2:ERG fusion in non-malignant prostate epithelial cells. Cancer Res. 70, 9544-9548 (2010).
134. Haffner, M. C. et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat. Genet. 42, 668-675 (2010).
135. Haffner, M. C. et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat. Genet. 42, 668-675 (2010).
136. Lee, K., Chae, J. Y., Kwak, C., Ku, J. H. & Moon, K. C. TMPRSS2-ERG gene fusion and clinicopathologic characteristics of Korean prostate cancer patients. Urology 76, 1268 e7-13 (2010).
137. Miyagi, Y. et al. ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples. Mod. Pathol. 23, 1492-1498 (2010).
138. Magi-Galluzzi, C. et al. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of caucasian, african-american and japanese patients. Prostate 71, 489-497 (2011).
139. Perner, S. et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 66, 8337-8341 (2006). (Pubitemid 44449140)
140. Paulo, P. et al. FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer. Genes Chromosomes Cancer 51, 240-249 (2012).
141. Tomlins, S. A. et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 66, 3396-3400 (2006).
142. Pflueger, D. et al. N.-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia 11, 804-811 (2009).
143. Pflueger, D. et al. Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. Genome Res. 21, 56-67 (2011).
144. Palanisamy, N. et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat. Med. 16, 793-798 (2010).
145. Maher, C. A. et al. Chimeric transcript discovery by paired-end transcriptome sequencing. Proc. Natl Acad. Sci. USA 106, 12353-12358 (2009).
146. Ren, G. et al. Identification of frequent BRAF copy number gain and alterations of RAF genes in Chinese prostate cancer. Genes Chromosomes Cancer 51, 1014-1023 (2012).
147. Mao, X. et al. Chromosome rearrangement associated inactivation of tumour suppressor genes in prostate cancer. Am. J. Cancer Res. 1, 604-617 (2011).
148. Gronberg, H. Prostate cancer epidemiology. Lancet 361, 859-864 (2003). (Pubitemid 36331852)
149. Oishi, K., Yoshida, O. & Schroeder, F. H. The geography of prostate cancer and its treatment in Japan. Cancer Surv. 23, 267-280 (1995).
150. Mehra, R. et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res. 67, 7991-7995 (2007). (Pubitemid 47395131)
151. Bostwick, D. G. et al. Independent origin of multiple foci of prostatic intraepithelial neoplasia: comparison with matched foci of prostate carcinoma. Cancer 83, 1995-2002 (1998). (Pubitemid 28503732)
152. Cheng, L. et al. Evidence of independent origin of multiple tumors from patients with prostate cancer. J. Natl Cancer Inst. 90, 233-237 (1998). (Pubitemid 28114542)
153. Mao, X. et al. Rapid high-resolution karyotyping with precise identification of chromosome breakpoints. Genes Chromosomes Cancer 46, 675-683 (2007). (Pubitemid 46802335)
154. Boyd, L. K. et al. High-resolution genome-wide copy-number analysis suggests a monoclonal origin of multifocal prostate cancer. Genes Chromosomes Cancer 51, 579-589 (2012).
155. Liu, W. et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat. Med. 15, 559-565 (2009).
156. Barry, M., Perner, S., Demichelis, F. & Rubin, M. A. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Urology 70, 630-633 (2007). (Pubitemid 350030260)
157. Suzuki, H. et al. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res. 58, 204-209 (1998). (Pubitemid 28047054)
158. Svensson, M. A. et al. Testing mutual exclusivity of ETS rearranged prostate cancer. Lab. Invest. 91, 404-412 (2011).
159. Magi-Galluzzi, C. et al. Heterogeneity of androgen receptor content in advanced prostate cancer. Mod. Pathol. 10, 839-845 (1997). (Pubitemid 27374856)
160. Penney, K. L. et al. Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin. Cancer Res. 15, 3223-3230 (2009).
161. Salinas, C. A. et al. Clinical utility of five genetic variants for predicting prostate cancer risk and mortality. Prostate 69, 363-372 (2009).
162. Wiklund, F. E. et al. Established prostate cancer susceptibility variants are not associated with disease outcome. Cancer Epidemiol. Biomarkers Prev. 18, 1659-1662 (2009).
163. Gallagher, D. J. et al. Susceptibility loci associated with prostate cancer progression and mortality. Clin. Cancer Res. 16, 2819-2832 (2010).
164. Kader, A. K. et al. Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate 69, 1195-1205 (2009).
165. Xu, J. et al. Association of prostate cancer risk variants with clinicopathologic characteristics of the disease. Clin. Cancer Res. 14, 5819-5824 (2008).
166. Zheng, S. L. et al. Cumulative association of five genetic variants with prostate cancer. N. Engl. J. Med. 358, 910-919 (2008). (Pubitemid 351397090)
167. Attard, G., de Bono, J. S., Clark, J. & Cooper, C. S. Studies of TMPRSS2-ERG gene fusions in diagnostic trans-rectal prostate biopsies. Clin. Cancer Res. 16, 1340 (2010).
168. Cuzick, J. et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 12, 245-255 (2011).
169. Shan, L. et al. The identification of chromosomal translocation, t(4;6)(q22;q15), in prostate cancer. Prostate Cancer Prostatic Dis. 13, 117-125 (2010).
170. Mao, X. et al. Detection of TMPRSS2:ERG fusion gene in circulating prostate cancer cells. Asian J. Androl. 10, 467-473 (2008). (Pubitemid 351596036)
171. Attard, G. et al. Characterization of, ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 69, 2912-2918 (2009).
172. Attard, G. et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 27, 253-263 (2008).
173. Tomlins, S. A. et al. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci. Transl. Med. 3, 94ra72 (2011).
174. Hessels, D. et al. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin. Cancer Res. 13, 5103-5108 (2007). (Pubitemid 47502077)
175. Hessels, D. & Schalken, J. A. The use of PCA3 in the diagnosis of prostate cancer. Nat. Rev. Urol. 6, 255-261 (2009).
176. Bussemakers, M. J. et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 59, 5975-5979 (1999). (Pubitemid 30004960)
177. Salami, S. S. et al. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol. Oncol. http://dX.doi.org/10.1016/j.urolonc.2011.04.001.
178. Nilsson, J. et al. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br. J. Cancer 100, 1603-1607 (2009).
179. Berney, D. M. et al. Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br. J. Cancer 100, 888-893 (2009).
180. Cuzick, J. et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br. J. Cancer 106, 1095-1099 (2012).
181. Nacusi, L. P. & Tindall, D. J. Targeting 5alpha-reductase for prostate cancer prevention and treatment. Nat. Rev. Urol. 8, 378-384 (2011).
182. de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995-2005 (2011).
183. Scher, H. I. et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 375, 1437-1446 (2010).
184. Tran, C. et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324, 787-790 (2009).
185. Carver, B. S. et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19, 575-586 (2011).
186. Tomlins, S. A. et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 13, 519-528 (2008). (Pubitemid 351763901)
187. Ateeq, B. et al. Therapeutic targeting of SPINK1-positive prostate cancer. Sci. Transl. Med. 3, 72ra17 (2011).
188. Shamash, J. et al. Chlorambucil and lomustine (CL56) in absolute hormone refractory prostate cancer: re-induction of endocrine sensitivity an unexpected finding. Br. J. Cancer 92, 36-40 (2005). (Pubitemid 40188433)
189. Barbieri, C. E., Demichelis, F. & Rubin, M. A. Molecular genetics of prostate cancer: emerging appreciation of genetic complexity. Histopathology 60, 187-198 (2012).
190. Witte, J. S. et al. Genomewide scan for prostate cancer-aggressiveness loci. Am. J. Hum. Genet. 67, 92-99 (2000). (Pubitemid 30481547)
191. Stanford, J. L. et al. Prostate cancer and genetic susceptibility: a genome scan incorporating disease aggressiveness. Prostate 66, 317-325 (2006). (Pubitemid 43191231)
192. Neville, P. J. et al. Prostate cancer aggressiveness locus on chromosome 7q32-q33 identified by linkage and allelic imbalance studies. Neoplasia 4, 424-431 (2002). (Pubitemid 34976958)
193. Paiss, T. et al. Linkage of aggressive prostate cancer to chromosome 7q31-33 in German prostate cancer families. Eur. J. Hum. Genet. 11, 17-22 (2003). (Pubitemid 36175779)
194. Slager, S. L. et al. Confirmation of linkage of prostate cancer aggressiveness with chromosome 19q. Am. J. Hum. Genet. 72, 759-762 (2003). (Pubitemid 36255976)
195. Neville, P. J. et al. Prostate cancer aggressiveness locus on chromosome segment 19q12-q13.1 identified by linkage and allelic imbalance studies. Genes Chromosomes Cancer 36, 332-339 (2003). (Pubitemid 36314516)
196. Johanneson, B. et al. Family-based association analysis of 42 hereditary prostate cancer families identifies the apolipoprotein L3 region on chromosome 22q12 as a risk locus. Hum. Mol. Genet. 19, 3852-3862 (2010).
197. Camp, N. J., Farnham, J. M. & Cannon-Albright, L. A. Localization of a prostate cancer predisposition gene to an 880-kb region on chromosome 22q12.3 in Utah high-risk pedigrees. Cancer Res. 66, 10205-10212 (2006). (Pubitemid 44672076)
198. Lindstrom, S. et al. Characterizing associations and SNP-environment interactions for GWAS-identified prostate cancer risk markers-results from BPC3. PLoS ONE 6, e17142 (2011).
199. Alvarado, C. et al. Somatic mosaicism and cancer: a micro-genetic examination into the role of the androgen receptor gene in prostate cancer. Cancer Res. 65, 8514-8518 (2005). (Pubitemid 41330620)
200. Sircar, K. et al. Androgen receptor CAG repeat length contraction in diseased and non-diseased prostatic tissues. Prostate Cancer Prostatic Dis. 10, 360-368 (2007). (Pubitemid 350238085)
201. Chang, B. L. et al. Polymorphic GGC repeats in the androgen receptor gene are associated with hereditary and sporadic prostate cancer risk. Hum. Genet. 110, 122-129 (2002).
202. Mononen, N. et al. Two percent of Finnish prostate cancer patients have a germ-line mutation in the hormone-binding domain of the androgen receptor gene. Cancer Res. 60, 6479-6481 (2000).
203. Kumazawa, T. et al. Microsatellite polymorphism of steroid hormone synthesis gene CYP11A1 is associated with advanced prostate cancer. Int. J. Cancer 110, 140-144 (2004). (Pubitemid 38507214)
204. Audet-Walsh, E. et al. SRD5A polymorphisms and biochemical failure after radical prostatectomy. Eur. Urol. 60, 1226-1234 (2011).
205. Cicek, M. S. et al. Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR. Prostate 59, 69-76 (2004). (Pubitemid 38387844)
206. Makridakis, N. M., Caldas Ferraz, L. F. & Reichardt, J. K. Genomic analysis of cancer tissue reveals that somatic mutations commonly occur in a specific motif. Hum. Mutat. 30, 39-48 (2009).
207. Akalu, A., Dlmajian, D. A., Highshaw, R. A., Nichols, P. W. & Reichardt, J. K. Somatic mutations at the SRD5A2 locus encoding prostatic steroid 5alpha-reductase during prostate cancer progression. J. Urol. 161, 1355-1358 (1999). (Pubitemid 29426156)
208. Rebbeck, T. R., Jaffe, J. M., Walker, A. H., Wein, A. J. & Malkowicz, S. B. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl Cancer Inst. 90, 1225-1229 (1998). (Pubitemid 28407089)
209. Mononen, N. et al. Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors. Cancer Res. 66, 743-747 (2006). (Pubitemid 43165937)
210. Suzuki, K. et al. Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population. Cancer 98, 1411-1416 (2003). (Pubitemid 37151495)
211. Chang, B. L. et al. Joint effect of HSD3B1 and HSD3B2 genes is associated with hereditary and sporadic prostate cancer susceptibility. Cancer Res. 62, 1784-1789 (2002).
212. Berndt, S. I. et al. Variant in sex hormone-binding globulin gene and the risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 16, 165-168 (2007). (Pubitemid 46174281)
213. de Muga, S. et al. Molecular alterations of EGFR and PTEN in prostate cancer: association with high-grade and advanced-stage carcinomas. Mod. Pathol. 23, 703-712 (2010).
214. Peraldo-Neia, C. et al. Epidermal growth factor receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer. BMC Cancer 11, 31 (2011).
215. Sun, X. et al. Genetic alterations in the PI3K pathway in prostate cancer. Anticancer Res. 29, 1739-1743 (2009).
216. Gray, I. C. et al. Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. Br. J. Cancer 78, 1296-1300 (1998). (Pubitemid 28495240)
217. Dong, J. T., Li, C. L., Sipe, T. W. & Frierson, H. F. Jr. Mutations of PTEN/MMAC1 in primary prostate cancers from Chinese patients. Clin. Cancer Res. 7, 304-308 (2001). (Pubitemid 32183034)
218. Alhopuro, P. et al. Somatic mutation analysis of MYH11 in breast and prostate cancer. BMC Cancer 8, 263 (2008).
219. Meyers, F. J. et al. Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors. Cancer 83, 2534-2539 (1998). (Pubitemid 29019574)
220. Zheng, P. P., Pang, J. C., Hui, A. B. & Ng, H. K. Comparative genomic hybridization detects losses of chromosomes 22 and 16 as the most common recurrent genetic alterations in primary ependymomas. Cancer Genet. Cytogenet. 122, 18-25 (2000).
221. Cooney, K. A., Wetzel, J. C., Consolino, C. M. & Wojno, K. J. Identification and characterization of proXimal 6q deletions in prostate cancer. Cancer Res. 56, 4150-4153 (1996). (Pubitemid 26305008)
222. Hughes, C., Murphy, A., Martin, C., Sheils, O. & O'Leary, J. Molecular pathology of prostate cancer. J. Clin. Pathol. 58, 673-684 (2005). (Pubitemid 40956818)
223. Chen, C., Bhalala, H. V., Vessella, R. L. & Dong, J. T. KLF5 is frequently deleted and down-regulated but rarely mutated in prostate cancer. Prostate 55, 81-88 (2003). (Pubitemid 36443994)
224. Cui, J. et al. Chromosome 7 abnormalities in prostate cancer detected by dual-color fluorescence in situ hybridization. Cancer Genet. Cytogenet. 107, 51-60 (1998). (Pubitemid 28506746)
225. Han, B. et al. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res. 68, 7629-7637 (2008).
226. Tomlins, S. A. et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448, 595-599 (2007). (Pubitemid 47206938)
227. Hermans, K. G. et al. Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer. Cancer Res. 68, 7541-7549 (2008).
228. Attard, G. et al. Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer. Br. J. Cancer 99, 314-320 (2008).
229. Helgeson, B. E. et al. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res. 68, 73-80 (2008). (Pubitemid 351380107)
230. Rickman, D. S. et al. SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. Cancer Res. 69, 2734-2738 (2009).